C4X Discovery Holdings Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 3/6
C4X Discovery Holdings has been growing earnings at an average annual rate of 16%, while the Life Sciences industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 47.1% per year. C4X Discovery Holdings's return on equity is 42.9%, and it has net margins of 42.8%.
Wichtige Informationen
16.0%
Wachstumsrate der Gewinne
44.8%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 36.9% |
| Wachstumsrate der Einnahmen | 47.1% |
| Eigenkapitalrendite | 42.9% |
| Netto-Marge | 42.8% |
| Letzte Ertragsaktualisierung | 31 Jan 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Here's Why We're Watching C4X Discovery Holdings' (LON:C4XD) Cash Burn Situation
Feb 07
Companies Like C4X Discovery Holdings (LON:C4XD) Are In A Position To Invest In Growth
Jul 05We're Not Very Worried About C4X Discovery Holdings' (LON:C4XD) Cash Burn Rate
Oct 07Companies Like C4X Discovery Holdings (LON:C4XD) Are In A Position To Invest In Growth
Mar 27We Think C4X Discovery Holdings (LON:C4XD) Can Afford To Drive Business Growth
Dec 12Aufschlüsselung der Einnahmen und Ausgaben
Wie C4X Discovery Holdings Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Jan 24 | 25 | 11 | 4 | 11 |
| 31 Oct 23 | 13 | 0 | 4 | 11 |
| 31 Jul 23 | 2 | -11 | 4 | 11 |
| 30 Apr 23 | 3 | -9 | 4 | 11 |
| 31 Jan 23 | 4 | -8 | 4 | 11 |
| 31 Oct 22 | 4 | -8 | 4 | 10 |
| 31 Jul 22 | 3 | -8 | 4 | 9 |
| 30 Apr 22 | 4 | -6 | 4 | 9 |
| 31 Jan 22 | 6 | -5 | 4 | 9 |
| 31 Oct 21 | 6 | -4 | 3 | 9 |
| 31 Jul 21 | 6 | -4 | 3 | 8 |
| 30 Apr 21 | 3 | -6 | 3 | 7 |
| 31 Jan 21 | 0 | -7 | 3 | 7 |
| 31 Oct 20 | 0 | -8 | 3 | 7 |
| 31 Jul 20 | 0 | -8 | 3 | 7 |
| 30 Apr 20 | 0 | -9 | 3 | 8 |
| 31 Jan 20 | 0 | -10 | 3 | 9 |
| 31 Oct 19 | 0 | -10 | 3 | 10 |
| 31 Jul 19 | 0 | -11 | 3 | 11 |
| 30 Apr 19 | 4 | -7 | 3 | 10 |
| 31 Jan 19 | 7 | -3 | 3 | 9 |
| 31 Oct 18 | 7 | -2 | 3 | 8 |
| 31 Jul 18 | 7 | -1 | 3 | 7 |
| 30 Apr 18 | 4 | -4 | 3 | 7 |
| 31 Jan 18 | 0 | -7 | 3 | 6 |
| 31 Oct 17 | 0 | -7 | 3 | 6 |
| 31 Jul 17 | 0 | -7 | 3 | 6 |
| 30 Apr 17 | 0 | -6 | 2 | 6 |
| 31 Jan 17 | 0 | -6 | 2 | 6 |
| 31 Oct 16 | 0 | -5 | 2 | 5 |
| 31 Jul 16 | 0 | -5 | 2 | 5 |
| 30 Apr 16 | 0 | -5 | 2 | 5 |
| 31 Jan 16 | 0 | -5 | 1 | 5 |
| 31 Oct 15 | 0 | -4 | 1 | 4 |
| 31 Jul 15 | 0 | -3 | 1 | 3 |
| 30 Apr 15 | 0 | -2 | 1 | 2 |
| 31 Jan 15 | 0 | -2 | 1 | 2 |
| 31 Oct 14 | 0 | -1 | 1 | 1 |
| 31 Jul 14 | 1 | -1 | 1 | 1 |
| 31 Jul 13 | 1 | 0 | 1 | 0 |
Qualität der Erträge: C4XD has a high level of non-cash earnings.
Wachsende Gewinnspanne: C4XD became profitable in the past.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: C4XD has become profitable over the past 5 years, growing earnings by 16% per year.
Beschleunigtes Wachstum: C4XD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Erträge im Vergleich zur Industrie: C4XD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: C4XD's Return on Equity (42.9%) is considered outstanding.